American Glaucoma Society Meeting
American Glaucoma Society Meeting
March 19, 2019
1 min read

Hydrus reduces medication burden in COMPARE trial

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

SAN FRANCISCO — Medication burden was significantly reduced more in glaucomatous eyes implanted with the Hydrus device vs. two iStent devices at 2 years postoperatively, according to COMPARE trial results presented here.

The multicenter randomized trial compared the Hydrus (Ivantis) with two iStent (Glaukos) devices for stand-alone primary surgical treatment of open-angle glaucoma. Patients under treatment with two or more medications whose IOP remained elevated after preoperative washout, between 23 mm Hg and 39 mm Hg, were randomized 1:1 in the operating room after gonioscopic assessment. Because of the off-label nature of the study, all cases were performed outside of the U.S.

“Both groups got lower pressure; both groups got less medication,” Thomas W. Samuelson, MD, said at the American Glaucoma Society annual meeting.

Both devices reduced medication use compared with preoperative rates; however, Hydrus eyes at 2 years demonstrated significantly greater reduction in medications as well as significantly more eyes completely off of medications.

Both devices were also deemed to achieve comparable procedural outcomes and safety, with “superb” implantation success rates, Samuelson said.

Significantly fewer eyes underwent re-operation in the Hydrus group, as well.

“No patient in the Hydrus group required secondary surgery at 12 or 24 months, while 2.6% of iStent patients required secondary surgery at 1 year and 9% at 2 years,” he said. – by Patricia Nale, ELS



Samuelson TW. Two-year results of a prospective, multicenter, randomized comparison of Hydrus vs. two iStents in standalone surgery for open angle glaucoma (COMPARE trial). Presented at: American Glaucoma Society annual meeting; March 14-17, 2019; San Francisco.

Disclosure: Samuelson reports he is a consultant for Glaukos and Ivantis.